Living with Type 1 diabetes is a numbers game. There’s not a moment in the day free from the burden of tracking your blood ...

DexCom (NASDAQ:DXCM) shares received an optimistic update from Redburn-Atlantic, with analyst Issie Kirby (NYSE:KEX) upgrading the stock from Neutral to Buy and increasing the price target to $115 ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Gross margin reflects inventory damage. Buoyed by the recent launch of Stelo and further upcoming CGM launches, Dexcom is anticipating a 14% growth in 2025 over 2024. Alphatec (ATEC) witnessed a ...

Notably, Dexcom continues to innovate, with a future iteration of its CGM on the way. Sayer described the next-generation ...

The job for Abbott, and competitors like Dexcom and Medtronic, is now to build awareness and make a business case for payers to cover these products, he said. Globally, that means CGM makers will ...

Strong Product Demand: We are upbeat about DexCom's continued strength in CGM products. DexCom demonstrated strong product demand in third-quarter 2024, highlighted by record new patient starts in ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the ...

SAN FRANCISCO—After spending the past year extending its portfolio of continuous glucose monitors to include people who may not have diabetes, Dexcom said it expects to see more than $4.03 ...

Dexcom’s focus on expanding continuous glucose monitoring access, rolling out new products like the Stelo, and its plans for international growth suggest promising opportunities for future ...